Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Business debt settlement

Doseology Shares-for-Debt Settlement, Director Resignation

Analysis based on 7 articles · First reported Sep 23, 2026 · Last updated Sep 23, 2026

Sentiment
0
Attention
0
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The impact on broader markets is negligible given the tiny dollar value of the settlement and the micro-cap status of Doseology Sciences Inc. Any effect is confined to the company's own shares on the Canadian Securities Exchange, where the modest dilution from 75,268 new shares at $0.18 may weigh marginally on the stock.

consumer products securities

Doseology Sciences Inc., a consumer product innovation company focused on oral pouch and functional stimulant product technologies, announced on September 23, 2026 that it proposes to issue an aggregate of 75,268 common shares at a deemed price of $0.18 per share to settle $13,548.39 in accrued share-based consulting compensation owed to a former consultant. The deemed issue price was determined by reference to the closing price of the company's common shares on the Canadian Securities Exchange on the trading day immediately preceding the announcement, in accordance with CSE policies. Subject to satisfaction of applicable corporate, securities law and CSE requirements, Doseology anticipates completing the settlement on or about September 30, 2026. The settlement shares will be subject to applicable resale restrictions under Canadian securities laws and any hold period imposed under CSE policies. Separately, the company announced that Daniel Vice has resigned as a director of the company, effective September 17, 2026. The company, led by CEO and Director Chris Jackson, wished Mr. Vice well in his future endeavours. The transaction is a small, routine administrative share issuance by a micro-cap issuer and carries negligible broader market significance.

70 Doseology Sciences Inc. proposed shares-for-debt settlement
40 Daniel Vice resigned as director Doseology Sciences Inc.
priv
The issuer proposing to settle $13,548.39 of accrued consulting compensation via 75,268 shares at $0.18, causing minor dilution. The resignation of a director adds a small governance change but no material operational effect.
Importance 100.0 Sentiment -5.0
per
Resigned as a director of Doseology Sciences Inc. effective September 17, 2026, a minor board change for the company.
Importance 40.0 Sentiment 0.0
exch
The exchange on which Doseology's shares trade and whose policies govern the deemed issue price and hold periods for the settlement shares.
Importance 30.0 Sentiment 0.0
per
CEO and Director of Doseology Sciences Inc., signing off on the announcement of the settlement and the director resignation.
Importance 20.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.